-
Mashup Score: 11FDA Approves Niraparib Plus Abiraterone Acetate for mCRPC - 9 month(s) ago
The FDA has approved niraparib plus abiraterone acetate, given with prednisone, for the treatment of adult patients with deleterious or suspected deleterious BRCA-positive, metastatic castration-resistant prostate cancer, as detected by an FDA-approved test.
Source: www.onclive.comCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 4PARP Inhibitor Plus Androgen Receptor Signaling Inhibitor Combinations: Will This Be The Future of mCRPC First-Line Therapy? - 10 month(s) ago
PARPi plus androgen receptor signaling inhibitor, metastatic castrate-resistant prostate cancer (mCRPC), PROpel, MAGNITUDE, TALAPRO-2, imaging-based progression-free survival, PARPi plus an ARSI in the first-line treatment setting for mCRPC.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
PARP inhibitor + AR signaling inhibitor combinations: Will this be the future of #mCRPC first-line therapy? #LibraryResource @RKSayyid @UofT and @zklaassen_md @GACancerCenter discuss data from the #PROpel, #MAGNITUDE, and #TALAPRO2 trials on UroToday > https://t.co/Lel4jqTXoV https://t.co/7xe3Vo9AtU
-
-
Mashup Score: 6FDA approves olaparib with abiraterone and prednisone - 11 month(s) ago
FDA approves olaparib with abiraterone and prednisone (or prednisolone) for BRCA-mutated metastatic castration-resistant prostate cancer
Categories: Latest Headlines, UrologyTweet-
And it’s finally out: FDA just approves olaparib+abiraterone for mCRPC pra with BRCA mut. #propel f/ ODAC recs. More news with #talapro2 #magnitude soon @FDAOncology ? @neerajaiims @AarmstrongDuke @DrChoueiri @GUONCGarciaJA @AarmstrongDuke @DrRanaMcKay https://t.co/0cmIbKj5ud
-
-
Mashup Score: 2
Alicia Morgans and Cora Sternberg discuss the MAGNITUDE phase 3 trial which was pragmatically designed to test the benefit of the combination of niraparib + abiraterone acetate/prednisone for metastatic castration-resistant prostate cancer (mCRPC) in patients prospectively identified with and without alterations in genes associated with HRR using both tissue and blood-based approaches. Dr….
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Combination of niraparib and abiraterone acetate + prednisone radiographic PFS as a first-line therapy in patients with HRR gene-mutated #mCRPC. @cnsternberg @WCMEnglanderIPM joins @CaPsurvivorship discussing the phase 3 #MAGNITUDE on UroToday > https://t.co/ZLhoC5fMd1 https://t.co/utIkPtOiHT
-
-
Mashup Score: 0
Alicia Morgans and Cora Sternberg discuss the MAGNITUDE phase 3 trial which was pragmatically designed to test the benefit of the combination of niraparib + abiraterone acetate/prednisone for metastatic castration-resistant prostate cancer (mCRPC) in patients prospectively identified with and without alterations in genes associated with HRR using both tissue and blood-based approaches. Dr….
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Combination of niraparib and abiraterone acetate + prednisone radiographic PFS as a first-line therapy in patients with HRR gene-mutated #mCRPC. @cnsternberg @WCMEnglanderIPM joins @CaPsurvivorship discussing the phase 3 #MAGNITUDE on UroToday > https://t.co/ZLhoC5gk2z https://t.co/ghCjMvEU8R
-
-
Mashup Score: 1A Pre-Specified Gene-by-Gene Analysis of Primary and Secondary Endpoints in the MAGNITUDE Clinical Trial - Shahneen Sandhu - 1 year(s) ago
Join Shahneen Sandhu and Alicia Morgans as they discuss the MAGNITUDE trial and the pre-specified gene-by-gene analysis that Dr Sandhu presented at ASCO 2022. Dr. Sandhu kicks off the conversation with a recap of the MAGNITUDE trial. She then explains how this follow-up study was a pre-specified analysis that looked at the primary endpoints and all the secondary endpoints in patients with at…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
A pre-specified gene-by-gene analysis of primary and secondary endpoints in the #MAGNITUDE clinical trial. @SandhuShahneen @PeterMacCC joins @CaPsurvivorship @DanaFarber in this conversation on UroToday > https://t.co/F1OoF6AAgk https://t.co/546rG2cFGx
-
-
Mashup Score: 1
Alicia Morgans and Cora Sternberg discuss the MAGNITUDE phase 3 trial which was pragmatically designed to test the benefit of the combination of niraparib + abiraterone acetate/prednisone for metastatic castration-resistant prostate cancer (mCRPC) in patients prospectively identified with and without alterations in genes associated with HRR using both tissue and blood-based approaches. Dr….
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Combination of niraparib and abiraterone acetate + prednisone radiographic PFS as a first-line therapy in patients with HRR gene-mutated #mCRPC. @cnsternberg @WCMEnglanderIPM joins @CaPsurvivorship discussing the phase 3 #MAGNITUDE on UroToday > https://t.co/ZLhoC5fMd1 https://t.co/qWZPJgKFBp
-
-
Mashup Score: 6
ASCO GU 2023 interim analysis of MAGNITUDE, combination of niraparib and abiraterone acetate/prednisone in patients with metastatic castrate-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Niraparib with abiraterone acetate and prednisone in patients with #mCRPC and homologous recombination repair gene alterations: second interim analysis of #MAGNITUDE. Presented by @EfstathiouEleni @MethodistHosp. @ASCO #GU23 written coverage > https://t.co/HPA8LIqm8h @rksayyid https://t.co/EBLNvQjDxd
-
-
Mashup Score: 0
ASCO GU 2023 abiraterone and niraparib for men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations, MAGNITUDE trial, BRCA alterations.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Impact of run-in treatment with abiraterone acetate and prednisone in the #MAGNITUDE study of niraparib and AAP in pts with #mCRPC and homologous recombination repair gene alterations. Presented by @Ecastromarcos. @ASCO #GU23 coverage by @WallisCJD > https://t.co/c50HPbPUzG https://t.co/0dHn3vorwX
-
-
Mashup Score: 1A Pre-Specified Gene-by-Gene Analysis of Primary and Secondary Endpoints in the MAGNITUDE Clinical Trial - Shahneen Sandhu - 1 year(s) ago
Join Shahneen Sandhu and Alicia Morgans as they discuss the MAGNITUDE trial and the pre-specified gene-by-gene analysis that Dr Sandhu presented at ASCO 2022. Dr. Sandhu kicks off the conversation with a recap of the MAGNITUDE trial. She then explains how this follow-up study was a pre-specified analysis that looked at the primary endpoints and all the secondary endpoints in patients with at…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
A pre-specified gene-by-gene analysis of primary and secondary endpoints in the #MAGNITUDE clinical trial. @SandhuShahneen @PeterMacCC joins @CaPsurvivorship @DanaFarber in this conversation on UroToday > https://t.co/F1OoF6AAgk https://t.co/PJC67ShEpZ
-
Breaking FDA approval — niraparib-abiraterone for BRCA-mutated #prostatecancer! One hybrid pill, ease of treatment. Congrats to the #MAGNITUDE team @JanssenUSOncMed! https://t.co/5rnBSRog7E @PCFnews @urotoday @ZEROCancer https://t.co/bazmiE2flQ